| Zacks Company Profile for Curis, Inc. (CRIS : NSDQ) |
|
|
| |
| • Company Description |
| Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.
Number of Employees: 34 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $1.93 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 137,497 shares |
| Shares Outstanding: 10.46 (millions) |
| Market Capitalization: $20.19 (millions) |
| Beta: 3.60 |
| 52 Week High: $8.29 |
| 52 Week Low: $1.02 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-30.33% |
-32.93% |
| 12 Week |
47.33% |
23.92% |
| Year To Date |
-36.93% |
-40.93% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
128 SPRING STREET BUILDING C SUITE 500
-
LEXINGTON,MA 02421
USA |
ph: 617-503-6500
fax: 617-503-6501 |
ir@curis.com |
http://www.curis.com |
|
|
| |
| • General Corporate Information |
Officers
James E. Dentzer - President; Chief Executive Officer and Director
Martyn D. Greenacre - Chairman
Diantha Duvall - Chief Financial Officer
Anne E. Borgman - Director
John A. Hohneker - Director
|
|
Peer Information
Curis, Inc. (CORR.)
Curis, Inc. (RSPI)
Curis, Inc. (CGXP)
Curis, Inc. (BGEN)
Curis, Inc. (GTBP)
Curis, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 231269309
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
|
|
Share - Related Items
Shares Outstanding: 10.46
Most Recent Split Date: 9.00 (0.05:1)
Beta: 3.60
Market Capitalization: $20.19 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-1.98 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-3.22 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/07/25 |
|
|
|
| |
